Quicksilver Biosciences is developing a CMOS-integrated biosensor platform for rapid genomic identification, utilizing proprietary sensing techniques to achieve target sensitivities that surpass current standards. This technology addresses the need for portable and cost-effective solutions in genomic analysis, enhancing accessibility for research and clinical applications.
Funding
$255.7K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current genomic identification methods often require bulky, expensive equipment and specialized laboratory settings, limiting accessibility and increasing the time required for analysis. This creates a need for more portable, cost-effective solutions that can be deployed in a wider range of environments.
Solution
Quicksilver Biosciences is developing a CMOS-integrated biosensor platform designed for rapid genomic identification. The platform utilizes proprietary sensing techniques to achieve high sensitivity in a portable and cost-effective format. This technology aims to enhance accessibility to genomic analysis for both research and clinical applications by reducing the reliance on traditional laboratory infrastructure. The biosensor platform is designed to provide quick and accurate results, enabling faster decision-making in various fields.
Target Audience
The primary target audience includes researchers and clinicians who require rapid and accessible genomic analysis tools.
Features
- CMOS-integrated biosensor for genomic identification.
- Proprietary sensing techniques for enhanced sensitivity.
- Portable form-factor for point-of-care applications.
- Cost-effective design for increased accessibility.